A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04392648 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision (no enrollment)

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG: TAK-573
DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Cyclophosphamide
DRUG: Dexamethasone

Sponsor

Teva Branded Pharmaceutical Products R&D LLC